Generic Lupron Depot Availability

See also: Generic Lupron Depot-PED

Lupron Depot is a brand name of leuprolide, approved by the FDA in the following formulation(s):

LUPRON DEPOT (leuprolide acetate - injectable;injection)

  • Manufacturer: ABBVIE ENDOCRINE INC
    Approval date: January 26, 1989
    Strength(s): 7.5MG/VIAL [RLD]
  • Manufacturer: ABBVIE ENDOCRINE INC
    Approval date: October 26, 1995
    Strength(s): 3.75MG [RLD]
  • Manufacturer: ABBVIE ENDOCRINE INC
    Approval date: December 22, 1995
    Strength(s): 22.5MG/VIAL [RLD]
  • Manufacturer: ABBVIE ENDOCRINE INC
    Approval date: March 7, 1997
    Strength(s): 11.25MG/VIAL [RLD]
  • Manufacturer: ABBVIE ENDOCRINE INC
    Approval date: May 30, 1997
    Strength(s): 30MG/VIAL [RLD]
  • Manufacturer: ABBVIE ENDOCRINE INC
    Approval date: June 17, 2011
    Strength(s): 45MG/VIAL

Has a generic version of Lupron Depot been approved?

No. There is currently no therapeutically equivalent version of Lupron Depot available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lupron Depot. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Sustained release microspheres and preparation thereof
    Patent 6,036,976
    Issued: March 14, 2000
    Inventor(s): Takechi; Nobuyuki & Ohtani; Seiji & Nagai; Akihiro
    Assignee(s): Takeda Chemical Industries, Ltd.
    Disclosed is a method of producing microspheres which comprises subjecting a w/o/w emulsion or o/w emulsion to an in-water drying method under the following conditions: 1) the amount of microspheres per m.sup.3 of an external aqueous phase is about 0.1 to about 500 kg, 2) the square root of the area (unit: m.sup.2) of the liquid surface in contact with the gas phase is about 0.2 to about 4.5 per the cube root of the volume (unit: m.sup.3) of an external aqueous phase, 3) the w/o/w emulsion or o/w emulsion is replaced at the replacement frequency of about 0.01 to about 10 times/minutes, 4) a gas is blown to the w/o/w emulsion or o/w emulsion at the gas transfer rate near the liquid surface of about 0.1 to about 300 m/second, and 5) the gas is replaced at the replacement frequency of not less than about 0.5 times/minutes; and the method of the present invention increases the rate of solvent removal from microspheres in in-water drying, reduces the amount of solvent in microspheres in a short time.
    Patent expiration dates:
    • December 13, 2016
    • December 13, 2016
      ✓ 
      Drug product
  • Controlled release composition and method of producing the same
    Patent 7,429,559
    Issued: September 30, 2008
    Inventor(s): Yamamoto; Kazumichi & Yamada; Akiko & Hata; Yoshio
    Assignee(s): Takeda Pharmaceutical Company Limited
    A controlled release composition containing a physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. A controlled release composition comprising (1) a physiologically active substance or salt thereof in an amount of about 14% (w/w) to about 24% (w/w) based on the total composition weight, (2) hydroxynaphthoic acid selected from the group consisting of 3-hydroxy-2-naphthoic acid and 1-hydroxy-2-naphthoic acid or salt thereof, and (3) a lactic acid polymer or salt thereof having a weight-average molecular weight of 15000 to 50000 in which the content of polymers having molecular weights of 5000 or less is about 5% by weight or less, wherein the molar ratio of said hydroxynaphthoic acid or salt thereof to said physiologically active substance or salt thereof is from 3:4 to 4:3.
    Patent expiration dates:
    • December 13, 2016
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web1)